Amgen Defends Tavneos Against FDA Withdrawal

Company Amgen Event Type Regulatory Defense Submission (FDA Withdrawal Hearing Request) Modality Oral Small-Molecule Complement C5a Receptor 1 Antagonist Asset Tavneos (avacopan) Target Complement C5a Receptor 1 (C5aR1) Disease Area Severe Active ANCA-Associated Vasculitis Summary Amgen submitted data and analyses to FDA on July 23…